BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Company Overview - BridgeBio Pharma Inc (NASDAQ: BBIO) develops treatments for genetic conditions [2] - The company's stock has increased by 46.5% since the previous article, primarily due to receiving approval for a treatment [2] Key Developments - BridgeBio Pharma Inc has experienced significant developments since the last analysis, contributing to its stock performance [2] Analyst Background - The author, Myriam Hernandez Alvarez, holds multiple degrees including a Ph.D. in computer applications and has a professional collaboration with Edgar Torres H [2]